Rosen Law Firm files class action lawsuit against Geron Corporation over misleading statements
- Rosen Law Firm announces a class action lawsuit for Geron Corporation investors.
- The lawsuit addresses misleading statements about the company’s product launch.
- Investors may be entitled to compensation without upfront costs by joining the class action.
In New York, on March 16, 2025, Rosen Law Firm, a prominent investor rights law firm, announced the filing of a class action lawsuit targeting Geron Corporation. The lawsuit pertains to purchasers of Geron securities between June 7, 2024, and February 25, 2025. Legal representatives aim to support investors who may have suffered losses due to Geron’s allegedly misleading statements regarding the success of its product, Rytelo. During the class period, investors were presented with overly optimistic claims that did not fully align with the actual market performance and challenges faced by Geron. These misrepresentations emphasized a successful launch and potential growth for Rytelo, a medication designed to inhibit the proliferation of malignant cells. However, it has been revealed that factors such as seasonality, existing competition, and monitoring burdens had more significant impacts on the patient onboarding process than the company disclosed. As a result, potential investors are encouraged to join the class action by contacting the Rosen Law Firm for further assistance regarding compensation claims. Meanwhile, the court deadline for those wishing to serve as lead plaintiffs is May 12, 2025, attracting attention from many affected parties. Rosen Law Firm’s history includes significant settlements in securities class action claims, established its expertise in this sector, further enticing victims to consider this legal remedy for losses incurred during the cited timeframe.